Výsledky vyhľadávania - "Paclitaxel/adverse effects"

Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer

Autori: Van Cutsem, Eric Collignon, Joëlle Eefsen, Rikke L a ďalší

Zdroj: Clin Cancer Res

Predmety: Male, Pancreatic Neoplasms/pathology, Oncologie, Carcinoma, Pancreatic Ductal/drug therapy, Deoxycytidine, ACTIVATION, Deoxycytidine/analogs & derivatives, Pancreatic Neoplasms/drug therapy, Antineoplastic Combined Chemotherapy Protocols, Paclitaxel/adverse effects, Human health sciences, Neoplasm Metastasis, Aged, 80 and over, CHEMORESISTANCE, Carcinoma, Pancreatic Ductal/immunology, Medicine (all), Middle Aged, Treatment Outcome, Oncology, Antibodies, Monoclonal, Humanized/adverse effects, Female, Pancreatic Neoplasms/immunology, Life Sciences & Biomedicine, Albumins/administration & dosage, Antibodies, Monoclonal, Humanized/administration & dosage, Carcinoma, Pancreatic Ductal, Adult, Paclitaxel, Clinical Trials: Targeted Therapy, Carcinoma, Pancreatic Ductal/pathology, Antibodies, Monoclonal, Humanized, Sciences de la santé humaine, POOR-PROGNOSIS, Paclitaxel/administration & dosage, 3211 Oncology and carcinogenesis, Albumins, Biomarkers, Tumor, Pancreatic Neoplasms/mortality, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Deoxycytidine/administration & dosage, Aged, Albumins/adverse effects, Science & Technology, Antineoplastic Combined Chemotherapy Protocols/adverse effects, IL1RAP protein, human, 3202 Clinical sciences, 130-nm albumin-bound paclitaxel, Gemcitabine, Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Interleukin-1 Receptor Accessory Protein, Deoxycytidine/therapeutic use

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39385434
https://lirias.kuleuven.be/handle/20.500.12942/769085
https://doi.org/10.1158/1078-0432.ccr-24-0645
https://hdl.handle.net/2268/333840
https://doi.org/10.1158/1078-0432.CCR-24-0645

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Autori: Mirza, Mansoor R Chase, Dana M Slomovitz, Brian M a ďalší

Prispievatelia: Mirza, Mansoor R Chase, Dana M Slomovitz, Brian M a ďalší

Zdroj: New England Journal of Medicine. 388:2145-2158

Predmety: Immune Checkpoint Inhibitors/administration & dosage, Endometrial Neoplasms/mortality, Neoplasm Recurrence, Local/etiology, Oncologie, DNA Mismatch Repair, Carboplatin, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Paclitaxel/adverse effects, Human health sciences, Humanized, Immune Checkpoint Inhibitors, Treatments in Oncology, Endometrial Neoplasms/drug therapy, Medicine (all), General Medicine, Hematology/Oncology, 3. Good health, Neoplasm Recurrence, Local/drug therapy, Local, Oncology, Antibodies, Monoclonal, Humanized/adverse effects, Humanized/administration & dosage, Female, Microsatellite Instability, Antibodies, Monoclonal, Humanized/administration & dosage, Paclitaxel, Antibodies, Monoclonal, Humanized, Sciences de la santé humaine, Antibodies, Endometrial Neoplasms/pathology, Local/drug therapy, Carboplatin/adverse effects, Immune Checkpoint Inhibitors/adverse effects, SDG 3 - Good Health and Well-being, Double-Blind Method, Paclitaxel/administration & dosage, Humans, dostarlimab, Antineoplastic Combined Chemotherapy Protocols/adverse effects, ICTS (Institute of Clinical and Translational Sciences), Carboplatin/administration & dosage, Gynecologic Oncology, Endometrial Neoplasms, Dostarlimab, Primary Advanced, Endometrial Cancer, Neoplasm Recurrence, Obstetrics/Gynecology, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Neoplasm Recurrence, Local, Endometrial Neoplasms/genetics

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/36972026
https://pure.eur.nl/en/publications/55cae580-ab6c-43f9-badc-ca5cc65928d0
https://doi.org/10.1056/NEJMoa2216334
https://portal.findresearcher.sdu.dk/da/publications/7d58112a-6fc6-4d99-ac41-bc03f85a9e49
https://doi.org/10.1056/NEJMoa2216334

Macular Cystoid Edema Induced by Nab-Paclitaxel

Autori: Jorge E. Moreira Carolina Vale Filipa Sampaio a ďalší

Zdroj: Acta Médica Portuguesa, Vol 35, Iss 4 (2022)

Predmety: Male, Albumins/adverse effects, Medicine (General), Paclitaxel, Adenocarcinoma, Middle Aged, Antineoplastic Agents, Phytogenic, Pancreatic Neoplasms, 03 medical and health sciences, R5-920, 0302 clinical medicine, Albumin-Bound Paclitaxel/adverse effects, Pancreatic Neoplasms/drug therapy, Albumins, Macular Edema/chemically induced, Paclitaxel/adverse effects, Medicine, Edema, Humans

Prístupová URL adresa: https://actamedicaportuguesa.com/revista/index.php/amp/article/download/13421/6399
https://pubmed.ncbi.nlm.nih.gov/34287143
https://doaj.org/article/f77993dfe5ed40c28d941d8ae626193c
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/13421
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/download/13421/6399
https://www.ncbi.nlm.nih.gov/pubmed/34287143

Neurofilament light chain as a biomarker of axonal damage in sensory neurons and paclitaxel-induced peripheral neuropathy in patients with ovarian cancer

Autori: Christina Mortensen Karina Dahl Steffensen Emma Simonsen a ďalší

Zdroj: Pain. 164:1502-1511

Predmety: Ovarian Neoplasms, Paclitaxel, Sensory Receptor Cells, Peripheral Nervous System Diseases/chemically induced, Induced Pluripotent Stem Cells, Intermediate Filaments, Ovarian Neoplasms/drug therapy, Peripheral Nervous System Diseases, 3. Good health, Carboplatin, 03 medical and health sciences, Carboplatin/adverse effects, 0302 clinical medicine, Neurofilament Proteins, Paclitaxel/adverse effects, Quality of Life, Humans, Female, Biomarkers, Retrospective Studies

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/36508173

Long‐term outcomes after paclitaxel‐coated balloon angioplasty of femoropopliteal arteries in Asian patients of the IN.PACT Global Study

Autori: Young‐Guk Ko Donghoon Choi Seung‐Woon Rha a ďalší

Prispievatelia: Young‐Guk Ko Donghoon Choi Seung‐Woon Rha a ďalší

Zdroj: Catheter Cardiovasc Interv

Predmety: Biocompatible, real-world, Time Factors, clinically driven target lesion revascularization, Paclitaxel, Balloon* / adverse effects, peripheral artery disease, paclitaxel, Peripheral Arterial Disease, 03 medical and health sciences, 0302 clinical medicine, Cardiovascular Agents* / adverse effects, Coated Materials, Biocompatible, Popliteal Artery / diagnostic imaging, Humans, Popliteal Artery, Prospective Studies, Vascular Patency, Paclitaxel / adverse effects, Pediatric and Congenital Heart Disease, Asian, Angioplasty, Coated Materials, Femoral Artery / diagnostic imaging, Cardiovascular Agents, 16. Peace & justice, 3. Good health, Femoral Artery, Treatment Outcome, Peripheral Arterial Disease* / diagnostic imaging, drug-coated balloons, Vascular Access Devices, Angioplasty, Balloon, Peripheral Arterial Disease* / therapy

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/36385562

Impaired liver function: effect on paclitaxel toxicity, dose modifications and overall survival: effect on paclitaxel toxicity, dose modifications and overall survival

Autori: Marieke Schmidt Robin Vernooij Merel van Nuland a ďalší

Prispievatelia: Marieke Schmidt Robin Vernooij Merel van Nuland a ďalší

Zdroj: BMC Cancer
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)

Predmety: Male, Adult, Paclitaxel, Esophageal Neoplasms, Observational Study, Antineoplastic Agents, Breast Neoplasms, Phytogenic/adverse effects, Paclitaxel toxicity, Dose-Response Relationship, Breast Neoplasms/drug therapy, SDG 3 - Good Health and Well-being, Liver Function Tests, Liver/drug effects, Journal Article, Paclitaxel/adverse effects, Humans, Antineoplastic Agents, Phytogenic/adverse effects, RC254-282, Retrospective Studies, Aged, Ovarian Neoplasms, Dose-Response Relationship, Drug, Research, Ovarian Neoplasms/drug therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, Antineoplastic Agents, Phytogenic, 3. Good health, paclitaxel dose modifications, Liver, Impaired liver function, Female, Drug, Esophageal Neoplasms/drug therapy

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39696046
https://doaj.org/article/2b9726aa8fcb4223954dae437cfcce7e
https://dspace.library.uu.nl/handle/1874/459772

Impaired liver function: effect on paclitaxel toxicity, dose modifications and overall survival

Autori: Schmidt, Marieke Vernooij, Robin van Nuland, Merel a ďalší

Prispievatelia: Schmidt, Marieke Vernooij, Robin van Nuland, Merel a ďalší

Predmety: Adult, Aged, Antineoplastic Agents, Phytogenic/adverse effects, Breast Neoplasms/drug therapy, Dose-Response Relationship, Drug, Esophageal Neoplasms/drug therapy, Female, Humans, Liver Function Tests, Liver/drug effects, Male, Middle Aged, Ovarian Neoplasms/drug therapy, Paclitaxel/adverse effects, Retrospective Studies, Journal Article, Observational Study

Popis súboru: application/pdf

Relation: https://dspace.library.uu.nl/handle/1874/459772

Dostupnosť: https://dspace.library.uu.nl/handle/1874/459772

Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer

Autori: Teruhiko Yoshida K.H. Lee Jung-Gon Lee a ďalší

Prispievatelia: Teruhiko Yoshida K.H. Lee Jung-Gon Lee a ďalší

Zdroj: Annals of Oncology. 32:1137-1147

Predmety: Lung Neoplasms, Paclitaxel, Carboplatin / therapeutic use, bevacizumab, NSCLC, Carboplatin, Local / drug therapy, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Antineoplastic Combined Chemotherapy Protocols, Humans, Nivolumab / adverse effects, nivolumab, Paclitaxel / adverse effects, Carcinoma, Bevacizumab / adverse effects, Protein-Tyrosine Kinases, Lung Neoplasms* / drug therapy, 3. Good health, Bevacizumab, Neoplasm Recurrence, Nivolumab, Non-Small-Cell Lung* / drug therapy, Neoplasm Recurrence, Local

Prístupová URL adresa: http://www.annalsofoncology.org/article/S0923753421020524/pdf
https://pubmed.ncbi.nlm.nih.gov/34139272
https://snucm.elsevierpure.com/en/publications/nivolumab-with-carboplatin-paclitaxel-and-bevacizumab-for-first-l
https://www.annalsofoncology.org/article/S0923-7534(21)02052-4/fulltext
https://www.ncbi.nlm.nih.gov/pubmed/34139272
https://www.sciencedirect.com/science/article/pii/S0923753421020524
https://pubmed.ncbi.nlm.nih.gov/34139272/
https://www.annalsofoncology.org/article/S0923753421020524/pdf

A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis

Autori: Brufsky, A Kim, SB Zvirbule, Z a ďalší

Prispievatelia: Brufsky, A Kim, SB Zvirbule, Z a ďalší

Zdroj: Annals of Oncology. 32:652-660

Predmety: atezolizumab, Paclitaxel / adverse effects, Triple Negative Breast Neoplasms* / drug therapy, MEK inhibitor, programmed death-ligand 1 inhibitor, Paclitaxel, Triple Negative Breast Neoplasms, Antibodies, Monoclonal, Humanized, Antibodies, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Piperidines, Monoclonal, Humanized / therapeutic use, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Antineoplastic Combined Chemotherapy Protocols, triple-negative breast cancer, Azetidines, Humans, cobimetinib

Popis súboru: application/pdf

Prístupová URL adresa: http://www.annalsofoncology.org/article/S0923753421000934/pdf
https://pubmed.ncbi.nlm.nih.gov/33539944
https://findanexpert.unimelb.edu.au/scholarlywork/1504537-a-phase-ii-randomized-trial-of-cobimetinib-plus-chemotherapy--with-or-without-atezolizumab--as-first-line-treatment-for-patients-with-locally-advanced-or-metastatic-triple-negative-breast-cancer-(colet)--primary-analysis
https://www.ncbi.nlm.nih.gov/pubmed/33539944
https://www.annalsofoncology.org/article/S0923-7534(21)00093-4/fulltext
https://europepmc.org/article/MED/33539944
https://pubmed.ncbi.nlm.nih.gov/33539944/
https://www.annalsofoncology.org/article/S0923753421000934/pdf
http://hdl.handle.net/1942/34426

Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP

Autori: Gunnar Folprecht Karolin Trautmann Alexander Stein a ďalší

Zdroj: Br J Cancer

Predmety: Male, Paclitaxel, Medizin, Cetuximab, Middle Aged, Article, Progression-Free Survival, Carboplatin, 3. Good health, Survival Rate, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Neoplasms, Unknown Primary, Female, Paclitaxel/administration, Female [MeSH], Cancer, Aged [MeSH], Cancer therapy, Cetuximab/administration, Humans [MeSH], Progression-Free Survival [MeSH], Carboplatin/adverse effects [MeSH], Middle Aged [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH], Survival Rate [MeSH], Paclitaxel/adverse effects [MeSH], Male [MeSH], Neoplasms, Unknown Primary/drug therapy [MeSH], Carboplatin/administration, Cetuximab/adverse effects [MeSH], Aged

Prístupová URL adresa: https://www.nature.com/articles/s41416-020-01141-8.pdf
https://pubmed.ncbi.nlm.nih.gov/33235314
https://pubmed.ncbi.nlm.nih.gov/33235314/
https://www.ncbi.nlm.nih.gov/pubmed/33235314
https://www.nature.com/articles/s41416-020-01141-8
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884392
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884392
https://www.nature.com/articles/s41416-020-01141-8.pdf
https://repository.publisso.de/resource/frl:6471414
https://www.ncbi.nlm.nih.gov/pubmed/33235314
https://doi.org/10.1038/s41416-020-01141-8
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85096556979

Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort

Autori: Giovanni Torsello Konstantinos Stavroulakis Marianne Brodmann a ďalší

Prispievatelia: Giovanni Torsello Konstantinos Stavroulakis Marianne Brodmann a ďalší

Zdroj: J Endovasc Ther
JOURNAL OF ENDOVASCULAR THERAPY

Predmety: Male, Balloon / instrumentation, Time Factors, Constriction, Pathologic, Severity of Illness Index, Angioplastie, DISEASE, Iliac Artery and Lower Limb Interventions, COST-EFFECTIVENESS, 0302 clinical medicine, Peripheral Arterial Disease / physiopathology, Popliteal Artery* / diagnostic imaging, Coated Materials, Biocompatible, Femoral Artery* / diagnostic imaging, Ischemia, Medicine and Health Sciences, DIRECTIONAL ATHERECTOMY, ENDOPROSTHESIS, ELUTING STENTS, Popliteal Artery, NITINOL STENT IMPLANTATION, Prospective Studies, Registries, Popliteal Artery* / physiopathology, femoropopliteal segment, 2. Zero hunger, Paclitaxel / adverse effects, angioplasty, Intermittent Claudication / therapy, Peripheral Arterial Disease / diagnostic imaging, Middle Aged, Limb Salvage, Constriction, Intermittent Claudication / physiopathology, popliteal artery, 3. Good health, Femoral Artery, Ischemia / physiopathology, Treatment Outcome, Female, Cardiovascular Agents / adverse effects, Paclitaxel, Balloon / adverse effects, CLAUDICATION, drug-coated balloon, Intermittent Claudication / diagnostic imaging, superficial femoral artery, peripheral artery disease, 12. Responsible consumption, PROXIMAL POPLITEAL ARTERIES, Cardiovascular Agents / administration & dosage, mortality, target lesion revascularization, Aged, Angioplasty, Balloon, Cardiovascular Agents, Humans, Intermittent Claudication, Peripheral Arterial Disease, Recovery of Function, Vascular Patency, 03 medical and health sciences, Paclitaxel / administration & dosage, Femoral Artery* / physiopathology, Ischemia / diagnostic imaging, Pathologic, PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY, LESIONS, VIABAHN, Angioplasty, Ischemia / therapy, Coated Materials, Peripheral Arterial Disease / therapy, Biocompatible, angioplasty, drug-coated balloon, femoropopliteal segment, mortality, peripheral artery disease, popliteal artery, superficial femoral artery, target lesion revascularization

Popis súboru: application/pdf; pdf

Prístupová URL adresa: https://journals.sagepub.com/doi/pdf/10.1177/1526602820931477
https://pubmed.ncbi.nlm.nih.gov/32583749
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545651/
https://journals.sagepub.com/doi/full/10.1177/1526602820931477
https://pubmed.ncbi.nlm.nih.gov/32583749/
http://journals.sagepub.com/doi/10.1177/1526602820931477
https://researchportal.helsinki.fi/en/publications/three-year-sustained-clinical-efficacy-of-drug-coated-balloon-ang-2
https://journals.sagepub.com/doi/pdf/10.1177/1526602820931477
https://hdl.handle.net/10807/168229
https://doi.org/10.1177/1526602820931477
https://hdl.handle.net/11570/3179554
https://journals.sagepub.com/doi/epub/10.1177/1526602820931477
https://doi.org/10.1177/1526602820931477
https://hdl.handle.net/20.500.11769/521964
https://epub.ub.uni-muenchen.de/86980/
http://hdl.handle.net/1854/LU-8701779
https://biblio.ugent.be/publication/8701779/file/8701780
https://biblio.ugent.be/publication/8701779
http://doi.org/10.1177/1526602820931477

Paclitaxel-Coated Balloon for the Treatment of Infrainguinal Disease: 12-Month Outcomes in the All-Comers Cohort of BIOLUX P-III Global Registry: 12-Month Outcomes in the All-Comers Cohort of BIOLUX P-III Global Registry

Autori: Tepe G. Zeller T. Moscovic M. a ďalší

Zdroj: J Endovasc Ther
Journal of endovascular therapy, vol. 27, no. 2, pp. 304-315
Tepe, G, Zeller, T, Moscovic, M, Corpataux, J M, Christensen, J K, Keirse, K, Nano, G, Schroeder, H, Binkert, C A & Brodmann, M 2020, ' Paclitaxel-Coated Balloon for the Treatment of Infrainguinal Disease : 12-Month Outcomes in the All-Comers Cohort of BIOLUX P-III Global Registry ', Journal of Endovascular Therapy, vol. 27, no. 2, pp. 304-315 . https://doi.org/10.1177/1526602819898804

Predmety: critical limb ischemia, Male, chronic limb-threatening ischemia, drug-coated balloon, drug-eluting balloon, femoropopliteal segment, paclitaxel, peripheral artery disease, superficial femoral artery, Asia, Paclitaxel, Taxol, Lower and Upper Limb Interventions, Aged, Amputation, Surgical, Angioplasty, Balloon/adverse effects, Angioplasty, Balloon/instrumentation, Australia, Cardiovascular Agents/administration & dosage, Cardiovascular Agents/adverse effects, Coated Materials, Biocompatible, Equipment Design, Europe, Female, Femoral Artery/diagnostic imaging, Femoral Artery/physiopathology, Humans, Limb Salvage, Paclitaxel/administration & dosage, Paclitaxel/adverse effects, Peripheral Arterial Disease/diagnostic imaging, Peripheral Arterial Disease/physiopathology, Peripheral Arterial Disease/therapy, Popliteal Artery/diagnostic imaging, Popliteal Artery/physiopathology, Progression-Free Survival, Prospective Studies, Registries, Time Factors, Vascular Access Devices, Vascular Patency, Periphere arterielle Verschlusskrankheit, Peripheral Arterial Disease, 03 medical and health sciences, 0302 clinical medicine, Drug-eluting Stent, Femoropoplitealer Bypass, Ischämiesyndrom, Popliteal Artery, 2. Zero hunger, Cardiovascular Agents, Oberschenkelarterie, 3. Good health, Femoral Artery, Ischämie, Angioplasty, Balloon

Popis súboru: application/pdf; pdf

Prístupová URL adresa: https://journals.sagepub.com/doi/pdf/10.1177/1526602819898804
https://pubmed.ncbi.nlm.nih.gov/31989855
https://journals.sagepub.com/doi/pdf/10.1177/15266028211014307
https://pubmed.ncbi.nlm.nih.gov/31989855/
https://journals.sagepub.com/doi/pdf/10.1177/1526602819898804
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31989855/
https://findresearcher.sdu.dk:8443/ws/files/169699384/1526602819898804.pdf
https://moh-it.pure.elsevier.com/en/publications/paclitaxel-coated-balloon-for-the-treatment-of-infrainguinal-dise
https://hdl.handle.net/2434/736149
https://doi.org/10.1177/1526602819898804
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_24BE92B4DA110
https://serval.unil.ch/notice/serval:BIB_24BE92B4DA11
https://serval.unil.ch/resource/serval:BIB_24BE92B4DA11.P001/REF.pdf
https://findresearcher.sdu.dk:8443/ws/files/169699384/1526602819898804.pdf

Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform

Prispievatelia: Andrew H Ko Kyu-Pyo Kim Jens T Siveke a ďalší

Predmety: Adenocarcinoma* / drug therapy, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Carcinoma, Pancreatic Ductal* / drug therapy, Humans, Hyaluronoglucosaminidase / adverse effects, Paclitaxel / adverse effects, Pancreatic Neoplasms* / drug therapy, Pancreatic Neoplasms* / pathology, Stomach Neoplasms* / drug therapy, PD-L1, basket study, combination therapy, gastric cancer, hyaluronan, immunotherapy, pancreatic cancer, proof of concept

Relation: ONCOLOGIST; J02415; https://ir.ymlib.yonsei.ac.kr/handle/22282913/195585; T202304032

Dostupnosť: https://ir.ymlib.yonsei.ac.kr/handle/22282913/195585
https://doi.org/10.1093/oncolo/oyad022

Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.

Autori: Brockstein, B. Haraf, D.J. Stenson, K. a ďalší

Predmety: Adult, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Combined Modality Therapy, Female, Fluorouracil/administration & dosage, Fluorouracil/adverse effects, Granulocyte Colony-Stimulating Factor/administration & dosage, Head and Neck Neoplasms/pathology, Head and Neck Neoplasms/radiotherapy, Humans, Hydroxyurea/administration & dosage, Hydroxyurea/adverse effects, Male, Middle Aged, Paclitaxel/administration & dosage, Paclitaxel/adverse effects, Prognosis

Relation: Journal of Clinical Oncology; https://iris.unil.ch/handle/iris/75993; serval:BIB_166B9E4220F3; 000071747900046; 9469365

Dostupnosť: https://iris.unil.ch/handle/iris/75993

Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice

Autori: Mattson, K. Bosquee, L. Dabouis, G. a ďalší

Predmety: Adult Aged Antineoplastic Agents, Phytogenic/adverse effects/*therapeutic use Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology Female Humans Lung Neoplasms/*drug therapy/pathology Male Middle Aged Paclitaxel/adverse effects/*analogs & derivatives/therapeutic use Survival Analysis *Taxoids Treatment Outcome

Relation: Lung Cancer; https://iris.unil.ch/handle/iris/242950; serval:BIB_E925A77511CE; 000089584900006

Dostupnosť: https://iris.unil.ch/handle/iris/242950
https://doi.org/10.1016/S0169-5002(00)00122-7

Gene Expression Profiling of Cutaneous Injured and Non-Injured Nociceptors in SNI Animal Model of Neuropathic Pain.

Autori: Berta, T. Perrin, F.E. Pertin, M. a ďalší

Predmety: Animals, Biopsy, Caspase 6/metabolism, Computational Biology, Disease Models, Animal, Ganglia, Spinal, Gene Expression Profiling, Humans, Immunohistochemistry, Mice, Knockout, Neuralgia/etiology, Neuralgia/metabolism, Neuralgia/pathology, Nociceptors/metabolism, Nociceptors/pathology, Paclitaxel/adverse effects, Rats, Skin/injuries, Spinal Nerves/injuries, Transcriptome

Popis súboru: application/pdf

Relation: Scientific Reports; https://iris.unil.ch/handle/iris/195366; serval:BIB_8491E723675C; 000408441600091

Dostupnosť: https://iris.unil.ch/handle/iris/195366
https://doi.org/10.1038/s41598-017-08865-3

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.

Autori: Quoix, E. Zalcman, G. Oster, J.P. a ďalší

Prispievatelia: Quoix, E. Zalcman, G. Oster, J.P. a ďalší

Predmety: Adenocarcinoma/drug therapy, Adenocarcinoma/mortality, Aged, 80 and over, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carboplatin/administration & dosage, Carboplatin/adverse effects, Carcinoma, Non-Small-Cell Lung/drug therapy, Non-Small-Cell Lung/mortality, Squamous Cell/drug therapy, Squamous Cell/mortality, Deoxycytidine/administration & dosage, Deoxycytidine/analogs & derivatives, Drug Administration Schedule, Female, Humans, Lung Neoplasms/drug therapy, Lung Neoplasms/mortality, Male, Paclitaxel/administration & dosage, Paclitaxel/adverse effects, Survival Rate, Vinblastine/administration & dosage, Vinblastine/analogs & derivatives

Relation: The Lancet; https://iris.unil.ch/handle/iris/180046; serval:BIB_E0AEE46B6996; 000295548900024

Dostupnosť: https://iris.unil.ch/handle/iris/180046
https://doi.org/10.1016/S0140-6736(11)60780-0

Cancer, douleur et traitement [Cancer, pain and treatment].

Autori: Mazzocato, C.

Predmety: Adult, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Bone Neoplasms/complications, Bone Neoplasms/secondary, Breast Neoplasms/complications, Breast Neoplasms/drug therapy, Female, Humans, Neoplasms/complications, Neoplasms/drug therapy, Paclitaxel/administration & dosage, Paclitaxel/adverse effects, Pain/etiology, Pain Management/methods, Paraneoplastic Polyneuropathy/drug therapy, Paraneoplastic Polyneuropathy/etiology, Peripheral Nervous System Diseases/chemically induced

Relation: Revue médicale suisse; https://iris.unil.ch/handle/iris/162446; serval:BIB_67604C16DABA

Dostupnosť: https://iris.unil.ch/handle/iris/162446

High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel.

Autori: Crivellari, D. Pagani, O. Veronesi, A. a ďalší

Prispievatelia: Crivellari, D. Pagani, O. Veronesi, A. a ďalší

Predmety: Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Brain Neoplasms/chemically induced, Brain Neoplasms/epidemiology, Brain Neoplasms/mortality, Brain Neoplasms/pathology, Breast Neoplasms/drug therapy, Breast Neoplasms/pathology, Disease Progression, Docetaxel, Epirubicin/administration & dosage, Epirubicin/adverse effects, Female, Humans, Incidence, Liver Neoplasms/secondary, Middle Aged, Paclitaxel/administration & dosage, Paclitaxel/adverse effects, Paclitaxel/analogs & derivatives, Receptor, ErbB-2/analysis, Receptors, Estrogen/analysis, Retrospective Studies, Taxoids

Relation: Annals of Oncology; https://iris.unil.ch/handle/iris/142535; serval:BIB_D17DC3B0ECEE; 000167806000019

Dostupnosť: https://iris.unil.ch/handle/iris/142535
https://doi.org/10.1023/a:1011132609055

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Autori: Kohei Shitara Mustafa Özgüroğlu Yung-Jue Bang a ďalší

Prispievatelia: Kohei Shitara Mustafa Özgüroğlu Yung-Jue Bang a ďalší

Zdroj: The Lancet. 392:123-133

Predmety: Male, Survival rate, Esophageal Neoplasms, Adenocarcinoma - drug therapy, Esophageal Neoplasms/pathology, Adenocarcinoma - mortality, 0302 clinical medicine, humanized - adverse effects, Monoclonal, Paclitaxel - adverse effects, Paclitaxel/adverse effects, Esophageal neoplasms - mortality, Esophageal neoplasms - drug therapy, Adenocarcinoma/drug therapy, Treatment outcome, Middle aged, Infusions, Intravenous, Stomach Neoplasms/drug therapy, Adenocarcinoma/pathology, Esophagogastric Junction*/pathology, Humanized/therapeutic use, Stomach Neoplasms/pathology, Esophageal Neoplasms/drug therapy, humanized - therapeutic use, Middle Aged, 3. Good health, Survival Rate, Treatment Outcome, Esophagogastric junction - pathology, Adenocarcinoma/mortality, Female, Esophagogastric Junction, Esophageal Neoplasms/mortality, Intravenous, Stomach neoplasms - drug therapy, Infusions, Paclitaxel, monoclonal, Adenocarcinoma, Antibodies, Monoclonal, Humanized, Antibodies, Stomach neoplasms - pathology, 03 medical and health sciences, Esophageal neoplasms - pathology, Stomach Neoplasms, Paclitaxel/therapeutic use, Humans, Paclitaxel - therapeutic use, Aged, Neoplasm Staging, intravenous, Neoplasm staging, Humanized/adverse effects, Adenocarcinoma - pathology

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/29880231
https://ir.ymlib.yonsei.ac.kr/handle/22282913/167098
https://yonsei.pure.elsevier.com/en/publications/pembrolizumab-versus-paclitaxel-for-previously-treated-advanced-g
https://snucm.elsevierpure.com/en/publications/pembrolizumab-versus-paclitaxel-for-previously-treated-advanced-g
https://research.unipg.it/handle/11391/1480900
https://www.sciencedirect.com/science/article/pii/S0140673618312571
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31257-1/fulltext
https://hdl.handle.net/11391/1480900